InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,008.15
(
0.34%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1730
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: None

Wednesday, 06/08/2011 8:53:45 AM

Wednesday, June 08, 2011 8:53:45 AM

Post# of 177
Random thoughts on trial expansion




Testing PSI-7977 as a monotherapy is a bold statement yet I wouldn't expect this to be thought of as a future treatment option. It's more of a in-house default option in case there were safety issues with 7977 in combination with PSI-938. If 7977/938 proves safe the stronger resistance profile would make this combo the obvious choice.


The 8 week GT2/GT3 study with SOC shouldn't come as a surprise to most considering the incredible, previously reported results.


I'm happy to see them beginning to test GT1 nulls and I look forward to seeing those results.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up